Trial · NCT03284424
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response Rate (ORR) | Recurrent or Metastatic Cutaneous cSCC Cohort | 35.2 | 95% Confidence Interval 26.2 to 45.2 | Percentage of participants | |
| Objective Response Rate (ORR) | Locally Advanced Unresectable cSCC Cohort | 51.9 | 95% Confidence Interval 37.8 to 65.7 | Percentage of participants | |
| Duration of Response (DOR) | Recurrent or Metastatic Cutaneous cSCC Cohort | 1.6 | Full Range 1.2 to 24.7 | Months | |
| Duration of Response (DOR) | Locally Advanced Unresectable cSCC Cohort | 2.7 | Full Range 1.1 to 12.3 | Months | |
| Disease Control Rate (DCR) | Recurrent or Metastatic Cutaneous cSCC Cohort | 52.4 | 95% Confidence Interval 42.4 to 62.2 | Percentage of participants | |
| Disease Control Rate (DCR) | Locally Advanced Unresectable cSCC Cohort | 64.8 | 95% Confidence Interval 50.6 to 77.3 | Percentage of participants | |
| Progression-free Survival (PFS) | Recurrent or Metastatic Cutaneous cSCC Cohort | 5.7 | 95% Confidence Interval 3.1 to 8.5 | Months | |
| Progression-free Survival (PFS) | Locally Advanced Unresectable cSCC Cohort | 14.4 | 95% Confidence Interval 5.5 to 43.6 | Months | |
| Overall Survival (OS) | Recurrent or Metastatic Cutaneous cSCC Cohort | 23.8 | 95% Confidence Interval 13.4 to 30.9 | Months | |
| Overall Survival (OS) | Locally Advanced Unresectable cSCC Cohort | NA | 95% Confidence Interval 33.3 to NA | Months | |
| Number of Participants Who Experienced One or More Adverse Events (AEs) | Recurrent or Metastatic Cutaneous cSCC Cohort | 102 | Participants | ||
| Number of Participants Who Experienced One or More Adverse Events (AEs) | Locally Advanced Unresectable cSCC Cohort | 51 | Participants | ||
| Number of Participants Who Discontinued Study Treatment Due to AE | Recurrent or Metastatic Cutaneous cSCC Cohort | 20 | Participants | ||
| Number of Participants Who Discontinued Study Treatment Due to AE | Locally Advanced Unresectable cSCC Cohort | 11 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03284424/results